If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?Its been five months since I upgraded my rating on Wave Life Sciences Ltd. ( WVE ) from a Hold to a Buy, with shares trading at $7. There has been some volatility since - mainly toEdmund Ingham is a biotech consult ...

S-1/A 1 lxrp_s1a.htm FORM S-1/A As filed with the Securities and Exchange Commission on December 5, 2025 Registration No. 333-290862 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to Form S-1 UNDER THE SECURITIES ACT OF 1933 LEXARIA BIOSCIENCE CORP. (Exact Name of Registrant as Specified in its Charter) (State or other jurisdiction of incorporation or Nevada 2000 20-2000871 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification No.) ...

As filed with the U.S. Securities and Exchange Commission on December 5, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Blue Water Acquisition Corp. IV (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Cayman Islands 6770 N/A (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) 15 ...

Core Insights - Medicus Pharma Ltd. has entered into a warrant inducement agreement for the immediate exercise of all outstanding Series A and Series B Warrants issued on July 14, 2025 [1] Company Summary - Medicus Pharma Ltd. is a precision guided biotech/life sciences company focused on advancing clinical development programs of novel and potentially disruptive therapeutic assets [1] Transaction Details - Maxim Group LLC is acting as the exclusive Financial Advisor for the transaction [1]

Core Thesis - ImmunityBio, Inc. is positioned to address significant medical challenges related to immune exhaustion and lymphopenia, with its flagship therapy Anktiva showing promising results in clinical trials [2][4]. Company Overview - ImmunityBio's share price was $2.30 as of December 1st [1]. - The company focuses on enhancing immune function through innovative therapies, particularly targeting T-cell and NK-cell activation [2][3]. Product and Technology - Anktiva, an IL-15 agonist, has demonstrated durable lymphopenia reversal and significant survival benefits in clinical trials, with median overall survival often doubling compared to historical standards [2]. - The technology platform allows for the autonomous production of IL-15 by engineered NK cells, creating a self-sustaining immune response [3]. Clinical Trials and Collaborations - Ongoing clinical trials, such as QUILT-3.055 for non-small cell lung cancer and QUILT-88 for pancreatic cancer, have shown promising results [2]. - Collaborations with MiNK Therapeutics have yielded exceptional outcomes in pancreatic cancer, highlighting Anktiva's potential as a key component in next-generation immunotherapy [4]. Market Position and Future Potential - Despite a weak balance sheet, ImmunityBio's platform presents significant asymmetric upside potential, particularly in light of the growing recognition of immune system exhaustion as a global health crisis [4]. - The founder, Dr. Patrick Soon-Shiong, has a proven track record in biotech, which adds credibility to the company's future prospects [4].

U.S. Stock Market Performance - U.S. stocks traded higher, with the Nasdaq Composite gaining around 0.2% on Friday [1] - The Dow increased by 0.17% to 47,933.71, while the NASDAQ rose 0.16% to 23,543.03, and the S&P 500 gained 0.15% to 6,867.40 [1] - Communication services shares jumped by 0.9%, while utilities stocks fell by 0.6% [1] Economic Indicators - The U.S. PCE price index increased by 0.3% month-over-month in September, consistent with the previous month and market estimates [2][11] - U.S. personal income rose by 0.4% month-over-month to $26.397 trillion in September [8] Commodity Market - Oil traded up 0.7% to $60.08, gold increased by 0.1% to $4,245.70, silver rose by 2.7% to $59.035, and copper gained 1.2% to $5.4385 [5] Company-Specific Movements - Praxis Precision Medicines Inc shares surged 31% to $248.00 after announcing completion of its pre-NDA meeting with the FDA [9] - DigitalBridge Group Inc shares increased by 32% to $12.86 following reports of SoftBank's interest in acquiring the company [9] - Rubrik Inc shares rose 23% to $86.80 after reporting better-than-expected third-quarter results and raising FY26 guidance [9] - Parsons Corp shares dropped 25% to $62.97 after losing a joint bid with IBM for a new air traffic control system [9] - Sportsman's Warehouse Holdings Inc shares fell 30% to $1.70 after reporting third-quarter results [9] - Domo Inc shares decreased by 23% to $8.87 after reporting third-quarter results and issuing lower-than-expected fourth-quarter sales guidance [9]

Core Viewpoint - XOMA Royalty Corporation has successfully completed the acquisition of Mural Oncology plc, with shareholders receiving $2.035 in cash per share as part of the transaction [1][2]. Acquisition Details - The acquisition was approved by Mural shareholders during a special meeting on October 24, 2025, and was sanctioned by the Irish High Court on December 3, 2025 [2]. - The acquisition became effective on December 5, 2025, following the delivery of the court order to the Irish Companies Registration Office [2]. Trading and Delisting - Mural's shares ceased trading on Nasdaq prior to the market opening on December 5, 2025, and the company plans to delist and deregister its shares under the Securities Exchange Act of 1934 [3]. Advisory Information - XOMA Royalty was advised by Gibson, Dunn & Crutcher LLP and Mason Hayes & Curran LLP, while Davy Corporate Finance UC acted as its financial advisor [4]. - Mural was advised by Lucid Capital Markets, LLC, with legal support from Wilmer Cutler Pickering Hale and Dorr LLP and Arthur Cox LLP [4]. Company Overview - XOMA Royalty Corporation operates as a biotechnology royalty aggregator, acquiring future economic rights associated with therapeutic candidates licensed to pharmaceutical or biotechnology companies [5]. - The company provides non-dilutive funding to sellers, enabling them to advance their internal drug candidates or for general corporate purposes [5].

NEW YORK, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: MLTX) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in MoonLake, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/moonlake-immunotherapeutics-class-action-lawsuit. Investors have until December 15, 2025, to as ...

Core Viewpoint - Capricor Therapeutics, Inc. has announced a public offering of 6,000,000 shares of common stock priced at $25.00 per share, aiming to raise approximately $150 million in gross proceeds to support its product development and general corporate purposes [1][2][3]. Group 1: Offering Details - The public offering consists of 6,000,000 shares at a price of $25.00 per share, with an additional 900,000 shares available for underwriters to purchase within 30 days [1] - The offering is expected to close around December 8, 2025, pending customary closing conditions [1] - Piper Sandler and Oppenheimer & Co. are the joint book-running managers, while H.C. Wainwright & Co. serves as the co-manager for the offering [2] Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for the continued development and manufacturing of product candidates, working capital, and general corporate purposes [3] Group 3: Company Overview - Capricor Therapeutics focuses on developing cell and exosome-based therapeutics, with its lead product candidate, Deramiocel, in late-stage clinical development for Duchenne muscular dystrophy (DMD) [6] - Deramiocel has shown significant immunomodulatory and anti-fibrotic effects in preserving cardiac and skeletal muscle function in DMD patients [6] - The company is also advancing its proprietary StealthX™ platform for targeted delivery of therapeutics, with applications in vaccinology and treatment of various diseases [6] Group 4: Regulatory and Commercialization - The offering is conducted under an effective shelf registration statement filed with the SEC, ensuring compliance with regulatory requirements [4] - Capricor has an exclusive agreement with Nippon Shinyaku Co., Ltd. for the commercialization and distribution of Deramiocel in the U.S. and Japan, pending regulatory approval [9]

Group 1 - Hims & Hers Health (HIMS) has expanded into Canada through the acquisition of Livewell, indicating a strategic move similar to previous expansions [1] - The acquisition aligns with Hims & Hers' focus on enhancing its market presence and diversifying its service offerings in the healthcare sector [1] Group 2 - The article emphasizes the importance of evaluating the science behind drug candidates and the competitive landscape in the biotech sector [1] - It highlights the potential for breakthrough science in biotechnology to lead to significant investment returns, while also noting the necessity for careful scrutiny [1]